Yoshitaka Tanaka
Directeur Technique/Scientifique/R&D chez NISSUI PHARMACEUTICAL CO., LTD.
Profil
Yoshitaka Tanaka has worked as a Director at CellGenTech, Inc. and as an Executive Officer & Research Manager at Nissui Pharmaceutical Co., Ltd.
Postes actifs de Yoshitaka Tanaka
| Sociétés | Poste | Début |
|---|---|---|
| NISSUI PHARMACEUTICAL CO., LTD. | Directeur Technique/Scientifique/R&D | - |
CellGenTech, Inc.
 CellGenTech, Inc. Pharmaceuticals: MajorHealth Technology CellGenTech, Inc. engages in the research and development of drugs for new gene therapy and regenerative medicine. It offers adipocyte-based medicine, technology for the development of gene/cell therapies. It also provides protein supplemental therapy solutions in the areas of hereditary diseases; orphan diseases; intractable diseases, such as lysosome and hemophilia; diabetics; arteriosclerotic diseases, and cancer or degenerative neuropathies. The company was founded by Masayuki Aso on October 20, 2003 and is headquartered in Chiba, Japan. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Nissui Pharmaceutical Co., Ltd.
 Nissui Pharmaceutical Co., Ltd. Medical SpecialtiesHealth Technology Nissui Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of culture media and diagnostic reagents for medical institutions, research organizations, and food industries. It operates through the Clinical Diagnostics and Pharmaceuticals segment. The Clinical Diagnostics segment provides reagents and instruments for microbiological and immunological tests. The Pharmaceuticals segment offers over-the-counter pharmaceutical products and health food supplements. The company was founded on April 6, 1935 and is headquartered in Tokyo, Japan. | Health Technology |
CellGenTech, Inc.
CellGenTech, Inc. Pharmaceuticals: MajorHealth Technology CellGenTech, Inc. engages in the research and development of drugs for new gene therapy and regenerative medicine. It offers adipocyte-based medicine, technology for the development of gene/cell therapies. It also provides protein supplemental therapy solutions in the areas of hereditary diseases; orphan diseases; intractable diseases, such as lysosome and hemophilia; diabetics; arteriosclerotic diseases, and cancer or degenerative neuropathies. The company was founded by Masayuki Aso on October 20, 2003 and is headquartered in Chiba, Japan. | Health Technology |
